Bio
Dr. Tan is a board-certified, fellowship-trained hematologist and oncologist at Stanford Health Care with a focus on treating lymphomas. She treats patients at the Palo Alto Veterans Affairs Healthcare System in the hematology department and she is also a clinical assistant professor in the Department of Medicine, Division of Oncology at Stanford University School of Medicine.
Clinical Focus
- Oncology
Professional Education
-
Board Certification: American Board of Internal Medicine, Hematology (2023)
-
Board Certification: American Board of Internal Medicine, Oncology (2023)
-
Fellowship: Stanford University Hematology and Oncology Fellowship (2022) CA
-
Board Certification: American Board of Internal Medicine, Internal Medicine (2019)
-
Residency: Duke University Internal Medicine Residency (2019) NC
-
Medical Education: University of California at San Francisco School of Medicine (2016) CA
-
Board Certification, American Board of Internal Medicine, Internal Medicine (2019)
-
Board Certification, American Board of Internal Medicine, Oncology (2020)
-
Board Certification, American Board of Internal Medicine, Hematology (2020)
-
Fellowship, Stanford University, Hematology/Oncology (2022)
-
Residency, Duke University, Internal Medicine (2019)
-
MD, University of California, San Francisco, Medicine (2016)
All Publications
-
Impact on caregivers and families of patients receiving chimeric antigen receptor T-cell therapy: a prospective longitudinal mixed methods study
SPRINGER. 2022: S145
View details for Web of Science ID 000922594700300
-
Do PROs Tell the Whole Story? Differential Outcomes Based on PatientReported Outcomes (PROs) Versus Performance-Based Metrics (PBM) on Cognition for Patients Receiving Chimeric Antigen Receptor (CAR)-T Cell Therapy
AMER SOC HEMATOLOGY. 2021
View details for DOI 10.1182/blood-2021-145746
View details for Web of Science ID 000736413904116
-
Worsening Financial Toxicity Among Patients Receiving Chimeric Antigen Receptor t-Cell (CAR-T) Therapy: A Mixed Methods Longitudinal Study
AMER SOC HEMATOLOGY. 2021
View details for DOI 10.1182/blood-2021-146032
View details for Web of Science ID 000736398802108
-
Preventing 30-day readmissions for patients with cancer: A root-cause analysis
LIPPINCOTT WILLIAMS & WILKINS. 2021
View details for DOI 10.1200/JCO.2020.39.28_suppl.226
View details for Web of Science ID 000707130200222
-
Feasibility Study Integrating Electronic Patient-Reported Outcomes (PROs) and Palliative Care for High-Risk Acute Myeloid Leukemia (AML) Patients
CIG MEDIA GROUP, LP. 2021: S279-S280
View details for Web of Science ID 000691910500447
-
Prospective Randomized Study of Advance Directives in Allogeneic Hematopoietic Cell Transplant Recipients.
Transplantation and cellular therapy
2021
Abstract
BACKGROUND: Patients undergoing allogeneic HCT are at risk for high morbidity and mortality. Advance directives (AD) allow patients to express wishes regarding their care at the end of life, but these are not completed in the majority of patients undergoing HCT, with only 44% of deceased allogeneic HCT recipients at this institution completing an AD in the past decade. Increasing AD completion rate can improve quality of care for allogeneic HCT recipients.OBJECTIVE: Evaluating whether an alternative AD instrument can increase AD completion rate and patient satisfaction.STUDY DESIGN: We conducted a prospective, randomized controlled study of the traditional California AD vs. the use of a novel Letter AD, the Stanford What Matters Most Letter, in adult allogeneic HCT recipients. Patients 18 years and older undergoing first allogeneic HCT at Stanford University were eligible. Prior to HCT conditioning, enrolled patients were randomly assigned to complete either the traditional AD or the Letter AD. The primary endpoint was AD completion; the chi-squared test was used to compare the AD completion rate between arms. Wilcoxon rank-sum tests were used to compare uncertainty, satisfaction with decision-making, and satisfaction with the AD.RESULTS: Of the total 212 patients who were eligible, 126 (59.4%) were enrolled and randomized. The mean age was 53.7 years; 57(45.2%) were female; 74 (58.7%) were non-Hispanic White. The overall AD completion rate was 71.4% and did not differ between the traditional and Letter AD arms (70.3% vs 72.6%, P= 0.78). Of those who completed the Letter AD, 66.7%, 42.2%, and 46.7% of patients wished to die gently/naturally, at home, and/or with hospice, respectively. The traditional AD found that 62.2% wished to not prolong life if recovery was unlikely. Opinion surveys did not find differences in levels of satisfaction between the traditional and Letter AD.CONCLUSION: Completion rates of AD on this study were high (71.4%) in comparison to historically reported completion rates and did not significantly differ based upon AD version.
View details for DOI 10.1016/j.jtct.2021.03.030
View details for PubMedID 33836311
-
Coffee Consumption and Colorectal Cancer Prognosis.
JAMA oncology
2021
View details for DOI 10.1001/jamaoncol.2020.8485
View details for PubMedID 33734282
-
Heterogeneous Definitions of Secondary Acute Myeloid Leukemia (AML) Yield Distinct Outcomes in Response to First-Line Treatment with Hypomethylating Agents (HMA) and Venetoclax (Ven)
2021
View details for DOI 10.1182/blood-2021-147886
-
The role of palliative care in the management of patients with lung cancer
LUNG CANCER MANAGEMENT
2020
View details for DOI 10.2217/lmt-2020-0016
View details for Web of Science ID 000553560300001
-
Venetoclax monotherapy for cutaneous blastic plasmacytoid dendritic cell neoplasm.
Annals of hematology
2020
View details for DOI 10.1007/s00277-020-04276-z
View details for PubMedID 32968828
-
Improved Outcomes of Octogenarians and Nonagenarians with Acute Myeloid Leukemia in the Era of Novel Therapies.
American journal of hematology
2020
View details for DOI 10.1002/ajh.25949
View details for PubMedID 32744731